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Abstract
Introduction One of the greatest problems with continuous
renal replacement therapy (CRRT) is early coagulation of the
filters. Few studies have monitored circuit function
prospectively. The purpose of this study was to determine the
variables associated with circuit life in critically ill children with
CRRT.
Methods A prospective observational study was performed in
122 children treated with CRRT in a pediatric intensive care unit
from 1996 to 2006. Patient and filter characteristics were
analyzed to determine their influence on circuit life. Data were
collected on 540 filters in 122 patients and an analysis was
performed of the 365 filters (67.6%) that were changed due to
circuit coagulation.
Results The median circuit life was 31 hours (range 1 to 293
hours). A univariate and multivariate logistic regression study
was performed to assess the influence of each one of the
factors on circuit life span. No significant differences in filter life
were found according to age, weight, diagnoses, pump, site of
venous access, blood flow rate, ultrafiltration rate, inotropic drug
support, or patient outcome. The mean circuit life span was
longer when the heparin dose was greater than 20 U/kg per
hour (39 versus 29.1 hours; P = 0.008), with hemodiafiltration
compared with hemofiltration (34 versus 22.7 hours; P  =
0.001), with filters with surface areas of 0.4 to 0.9 m2 (38.2
versus 26.1 hours; P = 0.01), and with a catheter size of 6.5
French or greater (33.0 versus 25.0 hours; P = 0.04). In the
multivariate analysis, hemodiafiltration, heparin dose of greater
than 20 U/kg per hour, filter surface area of 0.4 m2 or greater,
and initial creatinine of less than 2 mg/dL were associated with
a filter life of more than 24 and 48 hours. Total effluent rate of
greater than 35 mL/kg per hour was associated only with a filter
life of more than 24 hours.
Conclusion Circuit life span in CRRT in children is short but
may be increased by the use of hemodiafiltration, higher heparin
doses, and filters with a high surface area.
Introduction
Continuous renal replacement therapy (CRRT) is currently the
treatment of choice in critically ill adults and children with
acute renal failure, fluid overload, or multiorgan dysfunction as
it allows a steady removal of fluid, creatinine, urea, and other
substances and produces with less hemodynamic instability
than occurs with hemodialysis [1-5]. One of the greatest prob-
lems with CRRT is early coagulation of the filters, leading to
blood loss, decreased efficacy of the technique, increased
costs, and a greater risk of hemodynamic instability in the con-
nection [6,7]. Contact between the blood and an artificial sur-
face is the factor underlying the initiation of coagulation,
although other factors such as the number of blood flow
reductions [8], hemoconcentration, a high platelet count, tur-
bulent blood flow, and blood-air contact in the air-detection
chambers are also involved [9,10]. Few studies have moni-
tored circuit function prospectively in patients on CRRT
[9,10]. We conducted a prospective observational study to
determine those variables associated with circuit life in criti-
cally ill children treated by CRRT.
ACT = activated clotting time; CRRT = continuous renal replacement therapy.Critical Care    Vol 12 No 4    del Castillo et al.
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Materials and methods
A prospective observational study was performed in a pediat-
ric intensive care unit from 1996 through 2006. The study was
approved by the local institutional review board. Due to the
characteristics of the study, informed consent of patients was
not considered to be necessary. Patients requiring CRRT
were included prospectively. Data from those filters that had to
be changed because of circuit coagulation were analyzed. The
machines used for continuous venovenous renal replacement
therapy were the BSM32 (Hospal, Lyon, France) during the
first 5 years of the study and then the PRISMA (Hospal).
Venous access was secured by inserting a double-lumen cath-
eter into one of the central veins. The size of the catheters
depended on the size of the patient. Either polyacrylonitrile
AN69 (Hospal) or polysulfone (L.IN.C Medical Systems Ltd,
Leicester, UK) hollow-fiber hemofilters were used, depending
on the body surface area of the patient and on the pump
employed. Commercially prepared, bicarbonate-buffered
hemofiltration replacement fluid (Clearflex®; Bieffe Medital,
Senegue, Spain) was infused prefilter to compensate for fluid
losses, which were assessed clinically. Decisions on the use
of hemodiafiltration were the responsibility of the treating phy-
sician and were based on the patient's need for solute clear-
ance. Age, gender, weight, and diagnoses were recorded on
admission to the pediatric intensive care unit and pediatric risk
of mortality (PRISM), pediatric index of mortality (PIM), and
pediatric logistic organ dysfunction (PELOD) scores, lactic
acid, and need for inotropic drug support were recorded at the
beginning of the CRRT. The variables analyzed in order to
determine their influence on circuit life were catheter and
venous access used, blood flow rates, heparin dose, filter sur-
face area, filtration fraction, ultrafiltration rate, and total effluent
flow rate (ultrafiltration plus dialysis). The reasons why the fil-
ters stopped functioning were collected prospectively; filters
removed electively were excluded from the analysis. Anticoag-
ulation was performed according to our protocol. Circuits
were primed with 1 L of 0.9% NaCl to which 5,000 IU of
heparin was added. Because of active bleeding or severe
coagulopathy, anticoagulation was not performed in 15 filters.
The rest of the patients were anticoagulated. At the time CRRT
was initiated, a heparin bolus of 20 to 50 IU/kg was adminis-
tered, depending on the baseline activated clotting time
(ACT). Patients with a normal baseline ACT received a bolus
of 50 IU/kg and this was reduced to 20 IU/kg for a baseline
ACT of greater than 200 seconds. This was followed by a con-
tinuous heparin infusion via the pre-blood pump port, aiming to
maintain an ACT of between 150 and 200 seconds. No other
anticoagulation drug was administered.
Statistical analysis
The statistical analysis was performed using the SPSS (ver-
sion 15) statistical program (SPSS Inc., Chicago, IL, USA).
Analysis of normality was performed with the Kolmogorov-
Smirnov test. The chi-square test, Fisher exact test, Mann-
Whitney test, Kruskal-Wallis test, and analysis of variance
were used to compare the qualitative and quantitative varia-
bles and to assess the influence of each factor on circuit life
span. A multivariate logistic regression model was performed.
Results are expressed as the odds ratio and corresponding
95% confidence intervals. Significance was taken as a P value
of less than 0.05.
Results
During the study period, 122 patients were treated with
CRRT. The clinical and demographic data of these patients
are shown in Table 1. Data were collected on 540 filters, and
the analysis was performed using the 365 (67.6%) filters that
were changed because of signs of circuit coagulation (the fil-
ters were clotted, or there was an important increase in the fil-
ter pressure in the CRRT monitor, which suggest coagulation
of the filter). The median circuit life was 31 hours (range 1 to
293 hours). The analysis of the influence of each factor stud-
ied is presented in Table 2. Filter life was slightly longer in chil-
dren older than 12 months and with a weight of greater than
10 kg, although this difference did not reach statistical signifi-
cance. Hemofilter life did not correlate significantly with
patient diagnoses, initial creatinine and urea, site of venous
access, type of pump, blood flow rates, severity of illness
score, need for inotropic drug support, or final outcome, nor
were significant differences observed on comparing the sur-
face area of the filters or the size of catheter used. However,
significant differences in filter life were found on comparing the
use of catheters larger or smaller than 6.5 French and the use
of filters with surface areas larger or smaller than 0.4 m2 (Table
2). Mean circuit life proved to be significantly longer with
hemodiafiltration than with hemofiltration. Filter life was also
longer with a total effluent flow rate of greater than 35 mL/kg
per hour, ultrafiltration flow rates of less than 25 mL/kg per
hour, and filtration fractions of less than 10%, although these
differences did not reach statistical significance. The adminis-
tration of heparin doses of less than 10 U/kg per hour did not
lead to any difference in circuit life span but there was a signif-
icant increase in life span with doses of greater than 15 U/kg
per hour. There were no bleeding events related to heparin
dose. In the multivariate logistic regression analysis, hemodia-
filtration, heparin dose of greater than 20 U/kg per hour, filter
surface area of 0.4 m2 or greater, and an initial creatinine of
less than 2 mg/dL were associated with a filter life of more
than 24 and 48 hours. Total effluent rate of greater than 35
mL/kg per hour was associated only with a filter life of more
than 24 hours (Tables 3 and 4).
Discussion
The success of CRRT depends in part on maintenance of the
extracorporeal circuit [6,11]. CRRT circuit life span is low in
adults and children; in our study, we found values similar to
those reported previously in children and adults [12-15]. How-
ever, there are few studies that have prospectively monitored
circuit function in adult patients on CRRT [9,10] and only one
studied the influence of vascular access location and size onAvailable online http://ccforum.com/content/12/4/R93
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filter life in children [16]. When life span is evaluated, the main
problem appears to be filter coagulation [6,10,11,17-19]. Dur-
ing CRRT, blood passes through an extracorporeal circuit and
coagulation is activated. Anticoagulation is therefore neces-
sary. There are a number of agents that can be used to achieve
circuit anticoagulation [6,15,17-21] and, of these, heparin
Table 1
Data of patients and clinical characteristics (n = 122)
Median Range
Age, years 1.4 0.16–22
Weight, kg 8 2.5–85
Diagnoses Number Percentage
Cardiac surgery 54 44.2
Sepsis 22 18
Nephropaties 15 12.2
Oncologic diseases 10 8.2
Cardiopathies 86 . 5
Gastrointestinal surgery 3 2.4
Hemolytic-uremic syndrome 3 2.4
Metabolic diseases 3 2.4
Others 43 . 2
CRRT indication
Acute renal failure 51 42
Fluid overload 22 18
Acute renal failure plus fluid overload 39 32
Tumor lysis 54
Others 54
Median Range
Initial creatinine, mg/dL 2.4 0.1–7.8
Creatinine after 24 hours of CRRT, mg/dL 1.5 0.1–3.9
Initial urea, mg/dL 104 6–290
Urea after 24 hours of CRRT, mg/dL 67.2 11–199
Number Percentage
Mechanical ventilation 98 84.5
Inotropic drug support 89 73
Mean Standard deviation
PRISM score at the beginning of CRRT 14 8.3
PELOD score at the beginning of CRRT 14.6 8.0
Number of failed organs 3 72% >2 organs
Number Percentage
Survival 84 68.9
CRRT, continuous renal replacement therapy; PELOD, pediatric logistic organ dysfunction; PRISM, pediatric risk of mortality.Critical Care    Vol 12 No 4    del Castillo et al.
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Table 2
Factors associated with the circuit life span
Circuit life span, hours P value
Mean Standard deviation
Age
<12 months 29.1 32.8 0.33
>12 months 33.3 35.5
Weight
<10 kg 28.8 31.9 0.24
>10 kg 34.3 37.0
Period of time
1996–2001 27.0 25.0 0.43
2002–2006 32.8 37.4
Pump type
PRISMA 31.8 36.1 0.98
BSM32 29.0 27.1
Catheter size
Two 4 French catheters 12.5 8.6
Double-lumen 5 French Double-lumen 6.5 French 25.7 34.2 25.4 37.8 0.07
Double-lumen 8–9 French 22.8 20.8
Double-lumen 10–11 French 36.1 38.6
4–5 French 25.0 25.0 0.04
6.5–11 French 33.0 36.3
Venous access
Subclavian 34.2 27.6
Femoral 30.5 34.4
Jugular 21.2 21.9 0.12
Other 38.2 40.5
Blood flow rate
<50 mL per hour 29.9 34.5 0.33
>50 mL per hour 32.8 33.2
Filter surface area
0.04 m2 27.7 31.2
0.15 m2 20.6 14.5 0.18
0.4 m2 43.6 51
0.6 m2 37.7 36.8
0.9 m2 38.2 53.5
0.04–0.15 m2 26.1 28.7 0.01
0.4–0.6–0.9 m2 38.2 40.3
Filter membrane
Polysulphone 28.5 28.5 0.18Available online http://ccforum.com/content/12/4/R93
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Acrylonitrile 32.0 35.3
Anticoagulation
No heparine 31 16.6 0.15
Heparine 31 34.6
Heparine dose
<10 U/kg per hour 28.4 28.4 0.08
>10 U/kg per hour 34.5 34.4
<15 U/kg per hour 28.9 31.5 0.02
>15 U/kg per hour 35.5 38.9
<20 U/kg per hour 29.1 31.5 0.008
>20 U/kg per hour 39.0 42.7
Hemodiafiltration
Yes 34.0 36.6 0.001
No 22.7 24.0
Ultrafiltration rates
<25 mL/kg per hour 32.2 35.4 0.10
>25 mL/kg per hour 21.0 17.2
Filtration fraction
<10% 31.5 34.6 0.12
>10% 18.3 13.3
Total effluent flow rate
>35 mL/kg per hour 34.6 39.6 0.06
<35 mL/kg per hour 25.8 22.9
Initial creatinine
<2 mg/dL 32.4 26.5 36.0 22.3 0.39
>2 mg/dL
Initial urea
<60 mg/dL 30.9 34.1 0.99
>60 mg/dL 30.4 32.0
Mortality
Yes 32.6 36.8 0.94
No 30.2 32.6
PRISM score
<15 29.0 29.5 0.95
>14 36.1 41.7
Lactic acid
<4 mmol/L 28.7 29.9 0.91
>4 mmol/L 34.7 39
PRISM, pediatric risk of mortality.
Table 2 (Continued)
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continues to be the most widely employed [1,18]. The aim of
anticoagulation in our study was to maintain an ACT of
between 150 and 200 seconds. We found that the use of
higher doses increased circuit life span and we did not
observe an increase of bleeding. Other studies have also
found that the heparin dose is a significant independent pre-
dictor of filter life [10,19]. Although we did not observe any
major complications due to heparin use, patients with a risk of
bleeding can be managed without anticoagulation [1,22,23].
Some but not all studies have found that the use of sodium cit-
rate increases filter life compared with heparin
[6,13,15,17,19,24,25]. In a recent evidence-based review,
Oudemans-van Straaten and colleagues [19] recommended
that, if bleeding risk is not increased, unfractionated heparin
(with an activated partial thromboplastin time of 1 to 1.4 times
normal) or low-molecular-weight heparin (anti-Xa 0.25 to 0.35
IU/L) should be used (evidence grade E). CRRT without anti-
coagulation can be considered when coagulopathy is present
(grade D). To our knowledge, no randomized studies in criti-
cally ill patients on CRRT have evaluated the effect of catheter
site or size. Hackbarth and colleagues [16], in a pediatric reg-
istry, found that larger catheter diameter and jugular access
are associated with longer circuit life. A short large-caliber
catheter is preferable. Smaller-caliber catheters do not permit
high flows and are more likely to kink, leading to a greater risk
of system malfunction and coagulation. However, a more cen-
tral position of the tip of the catheter improves flow [6]. In our
study, increased filter life was found with larger-caliber cathe-
ters, although this factor did not reach statistical significance
in the multivariate analysis, nor were differences in filter life
found on comparing the different sites of catheter placement,
although the simultaneous influence of a number of factors
makes it difficult to analyze these results adequately.
Filter life was slightly longer in children over 1 year of age and
in those with a body weight of greater than 10 kg, probably
due to the larger caliber of the catheters used and the greater
surface area of filters; however, the differences were not sig-
nificant. We found a significant correlation between circuit life
span and filter surface area. Although the filter must be chosen
according to the patient's age and weight, a larger surface
Table 3
Multivariate analysis of circuit life span more than 24 hours
Factor P value Odds ratio 95% CI
Weight <10 kg 0.147 1.914 0.796–4.606
Catheter 6.5–11 French 0.051 1.933 0.996–3.749
Filter 0.4–0.9 m2 0.006 3.311 1.407–7.795
Initial creatinine <2 mg/dL 0.009 2.534 1.263–5.088
Heparine dose >20 U/kg per hour 0.031 2.026 1.065–3.852
Hemodiafiltration 0.001 4.162 1.781–9.726
Ultrafiltration <25 mL/kg per hour 0.224 1.811 0.696–4.710
Total effluent flow rate >35 mL/kg per hour 0.029 2.143 1.082–4.245
CI, confidence interval.
Table 4
Multivariate analysis of circuit life span more than 48 hours
Factor P value Odds ratio 95% CI
Weight <10 kg 0.074 2.486 0.916–6.742
Catheter 6.5–11 French 0.093 2.128 0.002–5.134
Filter 0.4–0.9 m2 <0.001 6.786 2.396–19.221
Initial creatinine <2 mg/dL 0.011 3.120 1.305–7.460
Heparine dose >20 U/kg per hour 0.007 3.148 1.361–7.279
Hemodiafiltration 0.004 5.473 1.715–17.469
Ultrafiltration <25 mL/kg per hour 0.455 1.812 0.381–8.618
Total effluent flow rate >35 mL/kg per hour 0.109 2.128 0.882–5.134
CI, confidence interval.Available online http://ccforum.com/content/12/4/R93
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area is associated with a longer life span. This might be
explained by the fact that membrane saturation could be
delayed by the presence of a larger filter surface area. These
filters permit higher blood flows, thus increasing capillary
shear forces and reducing protein layering, with the conse-
quent decrease in membrane clotting and the prolongation of
filter life [6]. In a prospective study, filters with longer hollow
fibers had a longer life and a lower transmembrane pressure
than filters with a larger cross-section. This may have been due
to a lower blood flow leading to an increase in blood viscosity
in a filter with a larger cross-section [26]. Although the type of
membrane can also affect filter coagulation, no studies, to our
knowledge, have analyzed the effect of this variable during
CRRT in critically ill patients. In our study, there were no differ-
ences between polysulfone and acrylonitrile membranes, but
the surface areas of the filters were different. We found no dif-
ference in filter life over the study period or on comparing the
two types of machine used. Although more modern machines
permit greater control of the process, more accurate adjust-
ment, and have more sensitive alarms, in our experience this
has not led to longer filter life. This lack of a difference between
the machines could be due in part to the fact that a higher per-
centage of filters with a smaller surface area were used with
the more modern machines. In adults, circuit life has been
found to be longer with continuous venovenous hemodialysis
than with continuous venovenous hemofiltration [27]. In one
study in children, hemodiafiltration showed longer circuit life
than hemofiltration [16]. In comparison with hemofiltration,
hemodiafiltration permits lower blood flow rates to be used
and causes less hemoconcentration to achieve the same sol-
ute clearance; this could explain the longer circuit life [6]. In
our patients, a total effluent flow rate of greater than 35 mL/kg
per hour was associated with a longer filter life, probably due
to the use of dialysis. This suggests that continuous veno-
venous hemodiafiltration can achieve sufficient fluid and sub-
stance interchange efficacy with a lower risk of coagulation.
However, a prospective survey in children did not find a corre-
lation between circuit survival and CRRT mode [13]. Using
lower ultrafiltration rates and lower filtration fractions could
prolong circuit life, minimizing the procoagulant effects of
hemoconcentration [6]. Although filtration fractions of up to
25% have been used by some groups, we currently use low
filtration fractions, though still achieving adequate clearances
and azotemic controls. In our study, there were no statistically
significant differences in relation to filtration fraction. Another
option for reducing the filtration fraction is to administer the
replacement fluid before the filter to reduce the hemoconcen-
tration. In two studies, predilution replacement was associated
with longer circuit survival [10,28]. In our study, we consist-
ently used predilution replacement and therefore are unable to
analyze the effect of this factor. Apart from the dose of heparin,
the multivariate study also revealed that a low creatinine at the
time of starting CRRT was associated with a longer filter life.
This could be due to the fact that patients with a higher creat-
inine required higher rates of ultrafiltration, which could have
led to increased filter coagulation. However, as the compari-
son was performed using the creatinine at the time of starting
CRRT and not with the creatinine level at the time of each
change of filter, these results must be viewed with caution.
Our study has certain limitations. It is an 11-year, descriptive,
epidemiological study that does not test any intervention and
it is possible that some differences could be due to the
changes in treatment over time. However, it is prospective in
design and aims to increase our understanding of the nature
and magnitude of a phenomenon that has been poorly
explained up to now. Second, when comparing heparin doses,
we did not study the patients' anticoagulation parameters.
Although it seems reasonable to consider that correct antico-
agulation rather than the dose of heparin could prolong the cir-
cuit life span, this conclusion cannot be drawn from our data.
In addition, it has not been possible to control the effect of
problems with the vascular access on filter life in this study;
this is one of the main causes of CRRT system malfunction [8],
particularly in infants. Another factor that could not be studied
is staff training. This is a determinant factor in the early recog-
nition of and response to pump alarms, having a significant
effect on filter life [6].
Conclusion
We conclude that, in children on CRRT, filter life can be
increased by the use of hemodiafiltration, high heparin doses,
and filters with a large surface area.
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